Drug intelligence / Profile preview

JTT-851

Development stage: Phase 2
Lead developer: Shionogi
Modality: Small Molecules
Administration: Oral

Overview

JTT-851 is an orally active small molecule drug developed as an agonist of the free fatty acid receptor 1 (FFAR1), also known as GPR40. It was designed to stimulate insulin secretion in a glucose-dependent manner, making it a potential antihyperglycemic agent for the treatment of type 2 diabetes mellitus. The drug was developed by Japan Tobacco and its subsidiary Akros Pharma. Clinical development reached Phase 2 trials in both Japan and the USA but was discontinued before reaching approval due to concerns over safety or efficacy[1][2][5]. As a G protein-coupled receptor agonist, JTT-851 acts by stimulating FFAR1/GPR40 on pancreatic beta cells, thereby enhancing insulin secretion in response to elevated blood glucose levels[1][4].

Other names: JTT 851JTT851JTT-851

Targets

FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on JTT-851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JTT-851.

Explore the full profile